Licensing · MENA · Announced 23 Jun 2026
Genetix Biotherapeutics → SPIMACO
Licensing deal between Genetix Biotherapeutics (United States) and SPIMACO (Saudi Arabia), covering lovotibeglogene autotemcel, announced 23 Jun 2026. Value: Undisclosed.
Parties: Genetix Biotherapeutics (United States) → SPIMACO (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia, GCC countries, and the broader Middle East region
- Therapeutic area
- Rare / Orphan
- Asset
- lovotibeglogene autotemcel , betibeglogene autotemcel
- Announced
- 23 Jun 2026
Our analysis
This transaction marks a significant milestone in expanding global patient access to highly advanced, one-time ex-vivo lentiviral vector gene addition cell therapies.
Historically, logistically complex therapies like LYFGENIA ™ and ZYNTEGLO ™ have been confined to Western markets.
The full analysis is free to read with a work email on this page.
Source: Business Wire